Alamar Biosciences IPO

alamarbio.comHealthcare / BioTech & Pharma

Alamar Biosciences is a biotechnology company that is striving to develop a precision proteomics platform that is used in protein biomarker detection. Their flagship technology platform is called NULISA (Nanoparticle Uninhibited Luminescent Immunoassay), and it aims to help researchers detect protein biomarkers down to attomolar concentrations, or extremely small amounts. Alamar Biosciences seeks to use the NULISA platform to increase the speed of development for new diagnostic tests that can detect diseases early and improve treatment options. Alamar Biosciences founded in 2018 and headquartered in Fremont, CA.

Buy or sell Alamar Biosciences stock Learn more about Alamar Biosciences stock

Learn more about Alamar Biosciences

Is Alamar Biosciences a publicly traded company?

Alamar Biosciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Alamar Biosciences go IPO?

Alamar Biosciences has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Alamar Biosciences's IPO price?

The IPO price for Alamar Biosciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Alamar Biosciences pre-IPO?

Alamar Biosciences is privately held company and is not publicly traded, therefor investing in Alamar Biosciences pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Alamar Biosciences shares?

To determine the value of your Alamar Biosciences shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Alamar Biosciences shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Alamar Biosciences before it goes public?

Yes, you can seek to sell shares in Alamar Biosciences while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Alamar Biosciences's funding to date?

Alamar Biosciences has raised $248.57MM to date.

When was Alamar Biosciences founded?

Alamar Biosciences was founded in 2018.

Who are Alamar Biosciences's major investors?

Qiming Venture Partners

Sherpa Healthcare Partners

Hercules Capital

Morningside Group

Samsara Biocapital

National Institutes of Health

Sands Capital

U.S. Department of Health and Human Services

Illumina Ventures

Terra Magnum Capital Partners

Alamar Biosciences funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
2/26/2024	Series C	$128.27MM raised	$XXX.XX	$XXX.XX
10/15/2021	Series B-Plus	$10MM raised	$XXX.XX	$XXX.XX
9/8/2021	Series B	$80MM raised	$XXX.XX	$XXX.XX
5/26/2020	Series A-1, A-2, A-3 and A-4	$30.3MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.